Eagle Pharmaceuticals Granted Patent for PEMFEXY®

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 ("the ‘813 patent") entitled "Pemetrexed Formulations." Eagle has submitted the patent for listing in the U.S. Food and Drug Administration's Orange Book.1 The ‘813 patent is directed to pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY®.

The ‘813 patent will expire in 2036. This is the second patent to be listed in the Orange Book for PEMFEXY, and to date Eagle has not received any notice of a Paragraph IV certification for an application referencing PEMFEXY.

"The issuance of this patent is meaningful, as we continue to vigorously protect the commercial success of PEMFEXY and to add to the overall strength of our patent portfolio. PEMFEXY maintains a unique J-Code from CMS and sales remain strong, with a 24% share in the commercial (non-340B) pemetrexed market leaving the third quarter of 2023," stated Scott Tarriff, President and Chief Executive Office of Eagle.

About PEMFEXY
PEMFEXY is a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin.

About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Related Press Releases
Happy Chinese New Year Tour Helped Ringing in the Lunar New Year with Seven Events in the United States to Showcase Chinese Craftsmanship and Art Forms

Happy Chinese New Year Tour Helped Ringing in the Lunar New...

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creativity for Everyone

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creat...

Lana Evanova's Impressionistic Acrylic Paintings Enchant the Art Community at Arte Fiera 2024

Lana Evanova's Impressionistic Acrylic Paintings Enchant the...

ToyHub247.com: A New Destination for Online Toy Shopping

ToyHub247.com: A New Destination for Online Toy Shopping

Embark on a New Era of Travel and Web3-Related Ecosystem with XINTEL – The Gateway to Unprecedented SocialFi

Embark on a New Era of Travel and Web3-Related Ecosystem wit...

Real Street Capital Announces Regulation A+ Offering to Raise $25 Million for REAL STREET BUILD-TO-RENT FUND I, LLC.

Real Street Capital Announces Regulation A+ Offering to Rais...

SASSA Status Check launched an updated tool for grant beneficiaries

SASSA Status Check launched an updated tool for grant benefi...

Announcing the Launch of Kosa Salon SF’s New Website: A New Luxury Hair Salon in San Francisco

Announcing the Launch of Kosa Salon SF’s New Website: A New...

PT TORAGRO TANI NUSANTARA Introduces Modern Inorganic And Liquid Organic Fertilizers

PT TORAGRO TANI NUSANTARA Introduces Modern Inorganic And Li...